89 related articles for article (PubMed ID: 20556477)
1. Survival among patients with primary central nervous system lymphoma, 1973-2004.
Norden AD; Drappatz J; Wen PY; Claus EB
J Neurooncol; 2011 Feb; 101(3):487-93. PubMed ID: 20556477
[TBL] [Abstract][Full Text] [Related]
2. Trends in primary central nervous system lymphoma incidence and survival in the U.S.
Shiels MS; Pfeiffer RM; Besson C; Clarke CA; Morton LM; Nogueira L; Pawlish K; Yanik EL; Suneja G; Engels EA
Br J Haematol; 2016 Aug; 174(3):417-24. PubMed ID: 27018254
[TBL] [Abstract][Full Text] [Related]
3. Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients.
Mahale P; Shiels MS; Lynch CF; Engels EA
Am J Transplant; 2018 Feb; 18(2):453-461. PubMed ID: 28805292
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
[TBL] [Abstract][Full Text] [Related]
5. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: A mirror type presentation in an immunocompetent patient.
Chávez EE; Arce JCD; Perea EDB; Pedraza AG; Ávila AIJ; Quezada DEA; Suárez PDG
Surg Neurol Int; 2024; 15():143. PubMed ID: 38741983
[TBL] [Abstract][Full Text] [Related]
8. Conditional survival of elderly primary central nervous system lymphoma.
Qian H; Yang Z; Cai L; Chen H
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13391-13401. PubMed ID: 37491638
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors of the Primary Central Nervous System Lymphoma: Clinical Experience from a Tertiary Care Center in the Middle East.
Ebrahimi H; Esfandbod M; Ketabchi SM; Yarandi KK; Shirani M; Amirjamshidi A; Alimohamadi M
Asian J Neurosurg; 2023 Mar; 18(1):36-39. PubMed ID: 37056898
[No Abstract] [Full Text] [Related]
10.
Zhou J; Zuo M; Li L; Li F; Ke P; Zhou Y; Xu Y; Gao X; Guan Y; Xia X; Yi X; Zhang X; Huang Y
Front Oncol; 2022; 12():824632. PubMed ID: 35223507
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma in the United States, 1975-2017.
Lv C; Wang J; Zhou M; Xu JY; Chen B; Wan Y
Ther Adv Hematol; 2022; 13():20406207211066166. PubMed ID: 35096360
[TBL] [Abstract][Full Text] [Related]
12. Nomograms for predicting cancer-specific survival in patients with primary central nervous system lymphoma: a population-based analysis.
Yang C; Ren X; Cui Y; Jiang H; Yu K; Li M; Zhao X; Zhu Q; Lin S
Ann Transl Med; 2021 Jul; 9(13):1055. PubMed ID: 34422967
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr Virus Infection in the Development of Neurological Disorders.
Soldan SS; Lieberman PM
Drug Discov Today Dis Models; 2020; 32(Pt A):35-52. PubMed ID: 33897799
[TBL] [Abstract][Full Text] [Related]
14. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.
Lurain K; Uldrick TS; Ramaswami R; Polizzotto MN; Goncalves PH; Widell A; Steinberg SM; Jaffe ES; Pittaluga S; Wang HW; Yuan CM; Tamula MA; Martin S; Wolters PL; George J; Little RF; Yarchoan R
Blood; 2020 Nov; 136(19):2229-2232. PubMed ID: 32609814
[No Abstract] [Full Text] [Related]
15. A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma.
Liu CJ; Lin SY; Yang CF; Yeh CM; Kuan AS; Wang HY; Tsai CK; Gau JP; Hsiao LT; Chen PM; Liu YC; Hong YC; Ko PS; Liu JH; Lin CH
Cancer Med; 2020 Mar; 9(6):2134-2145. PubMed ID: 32011103
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors and Survival in Primary Central Nervous System Lymphoma: A Population-Based Study.
Shan Y; Hu Y
Dis Markers; 2018; 2018():7860494. PubMed ID: 30050595
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System Lymphoma.
Gessler F; Bernstock JD; Behmanesh B; Brunnberg U; Harter P; Ye D; Friedman GK; Hansmann ML; Wagner M; Seifert V; Weise L; Marquardt G
Neurosurgery; 2019 Aug; 85(2):264-272. PubMed ID: 30016483
[TBL] [Abstract][Full Text] [Related]
19. Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Meling TR; Latysheva A; Da Broi M; Jahr G; Holte H; Beiske K; Emblem KE
Neuroradiology; 2018 Jul; 60(7):703-713. PubMed ID: 29804159
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.
Jahr G; Broi MD; Holte H; Beiske K; Meling TR
Brain Behav; 2018 Mar; 8(3):e00928. PubMed ID: 29541540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
